Skip to content

Advertising disclosure: We earn commissions from some of the products we link to. It never changes our scores or what we publish. Read the full disclosure

Tom’s Weight LossRankings
Not tested · not scored

Chia Health

Chia Health

Chia Health publishes a plainly accurate summary of the regulatory position: that compounded GLP-1s are not FDA-approved and that the FDA has restricted routine compounding now the semaglutide and tirzepatide shortages are resolved.

Sources captured · researched by Tom

Medications offered

As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.

  • SemaglutideType not stated
  • LiraglutideType not stated
  • TirzepatideType not stated

What they publish

Chia Health publishes 0 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers

Membership / programme fee
Pricing was not published on the page we captured
Medication cost
Not publicly disclosed on the pages we captured.
Introductory offer
Not publicly disclosed on the pages we captured.
Insurance
Not publicly disclosed on the pages we captured.
HSA / FSA
Not publicly disclosed on the pages we captured.
Consultation process
Not publicly disclosed on the pages we captured.
Eligibility
Not publicly disclosed on the pages we captured.
Lab work
Not publicly disclosed on the pages we captured.
Pharmacy fulfilment
Not publicly disclosed on the pages we captured.
Shipping
Not publicly disclosed on the pages we captured.
Support services
Not publicly disclosed on the pages we captured.
Cancellation
Not publicly disclosed on the pages we captured.
Refunds
Not publicly disclosed on the pages we captured.

What stands out

  • States correctly that compounded GLP-1s are not FDA-approved and that routine compounding has been restricted since the shortages were declared resolved. Many sellers still describe the shortage position as if it were current.
  • Describes the drug classes accurately, including tirzepatide as a GIP/GLP-1 agonist.
  • No pricing published on the page we captured.

Questions to ask before you pay

These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.

  • Establish pricing and which medication route you would actually be on.
  • An accurate regulatory summary is a good sign but is not the same as knowing what they dispense.

Limitations

  • No pricing published.

Sources

Captured . Pages change — check the current version before relying on anything here.

Worth comparing against

Brand-nameInsurance support

Peak Wellness

Peak Wellness

Publishes a written stance explaining why it does not use compounded GLP-1s

Membership
Not published
Medication
Not published
Publishes1/12 terms
Brand-nameInsurance support

MDLIVE

MDLIVE (Evernorth)

Major insurer-backed telehealth that states plainly it never uses compounded medication

Membership
Not published
Medication
Not published
Publishes2/12 terms
Brand-nameInsurance support

PlushCare

PlushCare (Accolade)

Primary-care physicians, FDA-approved medication, insurance accepted and no minimum commitment

Membership
Not published
Medication
Billed separately
Publishes7/12 terms